Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Conditions: Cytomegalovirus Infections; Transplant-Related Disorder Interventions: Drug: Letermovir 480 MG [Prevymis] Sponsors: University of Pennsylvania; Merck Sharp& Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials